drugset / Trial / NCT06394167

A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults

NCT06394167

Phase 1 Completed 88 enrolled Vertex Pharmaceuticals Incorporated
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of intravenously administered VX-993 at different doses in healthy participants.

Timeline

Start
2024-05-09
Primary completion
2025-02-18
Completion
2025-02-18

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-993 Unknown Intravenous

Indications

No indication recorded.